FDA 2025 Cancer Drug Approvals: targeted therapy dominates
Cancer drugs dominated 2025 FDA approvals, but many lack matching tests to identify which patients benefit, potentially delaying precision medicine access.
A comprehensive review of FDA 2025 cancer drug approvals shows cancer dominated at 35% of all approvals, with targeted therapies (especially kinase inhibitors and ADCs) driving growth and orphan drug/accelerated approval pathways widely utilized. A critical systemic gap identified is the frequent lack of concurrent companion diagnostic approval alongside new targeted therapies, potentially delaying patient access to appropriate precision medicine.
What the study was
- Study design
- Regulatory commentary/review
- Population
- Cancer patients receiving FDA-approved targeted therapies in 2025
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Exploration of Targeted Anti-tumor Therapy
Why it surfaced
Annual FDA cancer drug approval review useful for pipeline context; CDx gap finding has systemic implications for precision oncology access.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.